

SmartPA Criteria Proposal

Drug/Drug Class:	Synagis Clinical Edit
First Implementation Date:	October 1, 2003
Revised Date:	October 14, 2021
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of Synagis® (palivizumab) injection

Why Issue Selected: Synagis® (palivizumab) injection was FDA approved in June 1998 for the prevention of infection in high-risk pediatric patients due to respiratory syncytial virus (RSV), the most common cause of pneumonia and bronchiolitis in infancy and early childhood. Synagis is the first monoclonal antibody approved to provide passive immunity for an infectious disease. Severe RSV disease is the most common reason infants under 1 year of age are hospitalized in the United States. The American Academy of Pediatrics (AAP) recommends limiting the usage of Synagis to certain preterm infants and infants with certain chronic illnesses. During the 2020-2021 RSV Season (November through April) there were 560 MO HealthNet participants approved for Synagis.

Program-Specific Information:	Date Range FFS 11-01-2020 to 4-30-2021 (RSV Season)			
	Drug	Claims	Spend	Avg Spend per Claim
	SYNAGIS 50 MG/0.5 ML VIAL	812	\$1,411,645.30	\$1,738.47
	SYNAGIS 100 MG/1 ML VIAL	1,689	\$5,135,696.60	\$3,040.67

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Synagis® (palivizumab) injection
- Age range: All appropriate MO HealthNet participants ≤ 24 months of age

Approval Criteria

- Claim is during RSV Season (November through April) **AND**
- For prematurity:
 - Participant aged ≤ 12 months and born ≤ 28 weeks gestation **OR**

SmartPA Clinical Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

- Participant aged ≤ 6 months and born between 29 and 32 weeks gestation **OR**
- Participant aged ≤ 3 months and born between 32 and 35 weeks gestation **AND**
 - Enrolled in childcare **OR**
 - Has siblings that are < 5 years of age **OR**
- For chronic lung disease:
 - Participant aged < 12 months and born < 32 weeks gestation with chronic lung disease **AND**
 - required more than 21% oxygen for 28 days following birth **AND**
 - currently requiring medical therapy (oxygen on a continuous basis, bronchodilator, diuretic, corticosteroid or ventilator dependent) **OR**
 - Participant aged < 24 months and born < 32 weeks gestation with chronic lung disease **AND**
 - required more than 21% oxygen for 28 days following birth **AND**
 - required continued medical therapy throughout the past 6 months (oxygen on a continuous basis, bronchodilator, diuretic, corticosteroid or ventilator dependent) **OR**
- For congenital heart disease:
 - Participant aged ≤ 24 months with hemodynamically significant cyanotic and acyanotic congenital heart disease **AND**
 - Receiving medication to control CHF (digoxin, beta blockers, calcium channel blockers, ACE inhibitors, nitroglycerin, anti-coagulants, diuretics, or supplemental oxygen) **OR**
 - Moderate to severe pulmonary hypertension **OR**
 - Cyanotic heart disease **OR**
- For congenital abnormality of the airway or neuromuscular disease that impairs ability to clear secretions: Participant aged < 12 months **OR**
- For severe immunodeficiencies that may benefit from prophylaxis as determined by clinical consultant review: Participant aged ≤ 24 months

Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Therapy exceeds 5 doses per RSV season

Required Documentation

Laboratory Results:		Progress Notes:	
MedWatch Form:		Other:	X

Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)
 Rule Type: CE

Default Approval Period

Max of 5 doses per RSV season

References

- Synagis® (palivizumab) injection [package insert]. Gaithersburg, MD: MedImmune, LLC; May 2017.
- Clinical Pharmacology. Palivizumab – Synagis. Accessed May 13, 2021.
- Facts & Comparisons. Palivizumab Injection. Accessed May 13, 2021.
- Synagis® (palivizumab) Healthcare Professional Website. <https://www.synagis.com/patients/what-is-rsv.html>. Accessed May 13, 2021.

SmartPA Clinical Proposal Form
 © 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.